Radiation doses deriving from patients undergoing 111In-DTPA-D-Phe-1-octreotide scintigraphy

被引：0
|
作者：
Cormack, J [1 ]
机构：
[1] Flinders Med Ctr, Div Med Imaging, Bedford Pk, SA 5042, Australia
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE | 1998年 / 25卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：442 / 442
页数：1
相关论文
共 50 条
  • [21] Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide
    Forssell-Aronsson, E
    Bernhardt, P
    Nilsson, O
    Tisell, LE
    Wängberg, B
    Ahlman, H
    ACTA ONCOLOGICA, 2004, 43 (05) : 436 - 442
  • [22] [IN-111-DTPA-D-PHE(1)]OCTREOTIDE SCINTIGRAPHY IN THYROIDAL AND ORBITAL GRAVES-DISEASE - A PARAMETER FOR DISEASE-ACTIVITY
    POSTEMA, PTE
    KRENNING, EP
    WIJNGAARDE, R
    KOOY, PPM
    OEI, HY
    VANDENBOSCH, WA
    REUBI, JC
    WIERSINGA, WM
    HOOIJKAAS, H
    VANDERLOOS, T
    POUBLON, RML
    LAMBERTS, SWJ
    HENNEMANN, G
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (06): : 1845 - 1851
  • [23] Therapy using labelled somatostatin analogues:: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
    Barone, Raffaella
    Walrand, Stephan
    Konijnenberg, Mark
    Valkema, Roelf
    Kvols, Larry K.
    Krenning, Eric R.
    Pauwels, Stanislas
    Jamar, Francois
    NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (03) : 283 - 290
  • [24] Treatment of patients with neuroendocrine tumors with [111In-DTPA-D-Phe]-octreotide -: The Uppsala experience
    Janson, ET
    Garske, U
    Westlin, JE
    Welin, S
    Örlefors, H
    Granberg, D
    Skogseid, B
    Eriksson, B
    Öberg, K
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (02) : 294 - 295
  • [25] [IN-111-DTPA-D-PHE]OCTREOTIDE SCINTIGRAPHY (IN-SMS) IN NON-MEDULLARY THYROID-CARCINOMA
    DEHERDER, WW
    OEI, HY
    KWEKKEBOOM, DJ
    LAMBERTS, SWJ
    HENNEMAN, G
    KRENNING, EP
    JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (05) : P163 - P163
  • [26] [111In-DTPA-D-Phe]-OCTREOTIDE SCINTIGRAPHY IN METASTATIC HORMONE-REFRACTORY PROSTATIC ADENOCARCINOMA WITH HIGH CHROMOGRANIN A
    Villa, G.
    Borzone, C.
    Sambuceti, G.
    Carmignani, G.
    ANTICANCER RESEARCH, 2010, 30 (04) : 1537 - 1538
  • [27] DISTRIBUTION AND DOSIMETRY OF IN-111 DTPA-D-PHE-OCTREOTIDE IN MAN ASSESSED BY WHOLE-BODY SCINTIGRAPHY
    BAJC, M
    PALMER, J
    OHLSSON, T
    EDENBRANDT, L
    ACTA RADIOLOGICA, 1994, 35 (01) : 53 - 57
  • [28] DISTRIBUTION AND ELIMINATION OF THE SOMATOSTATIN ANALOG (IN-111-DTPA-D-PHE(1))-OCTREOTIDE (OCTREOSCAN111)
    ARNBERG, H
    WESTLIN, JE
    HUSIN, S
    NILSSON, S
    ACTA ONCOLOGICA, 1993, 32 (02) : 177 - 182
  • [29] Biodistribution of a new chelated somatostatin analogue, [In-111-DOTA-D-Phe-1-Tyr-3]-octreotide; Comparison with [In-111-DTPA-D-Phe-1]-octreotide in humans.
    Krenning, EP
    Bakker, WH
    Kwekkeboom, DJ
    Kooi, PPM
    vanderPluijm, ME
    Behe, M
    Macke, H
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 382 - 382
  • [30] [111In-DPTA-D-Phe1]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma
    Edgren, M
    Westlin, JE
    Kälkner, KM
    Sundin, A
    Nilsson, S
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1999, 14 (01) : 59 - 64
12345